Adma Biologics (ADMA) Total Liabilities (2011 - 2025)

Adma Biologics has reported Total Liabilities for 15 years, with the latest figure at $146.9 million in Q4 2025.

• For the quarter ending Q4 2025, Total Liabilities rose 5.2% year-over-year to $146.9 million; the trailing twelve-month figure through Dec 2025 stood at $146.9 million (up 5.2% YoY), and the FY2025 full-year result was $146.9 million, up 5.2% from the prior year.
• Total Liabilities for Q4 2025 stood at $146.9 million, up from $137.5 million in the prior quarter.
• The five-year high for Total Liabilities was $200.2 million in Q3 2022, with the low at $121.2 million in Q2 2021.
• Historically, Total Liabilities has averaged $166.2 million across 5 years, with a median of $170.6 million in 2022.
• Annual changes were most pronounced in 2022 — Total Liabilities soared 50.58% — and 2025, when it plunged 30.44%.
• Adma Biologics' Total Liabilities stood at $135.1 million in 2021, then jumped by 45.46% to $196.5 million in 2022, then decreased by 1.28% to $194.0 million in 2023, then declined by 28.0% to $139.7 million in 2024, then climbed by 5.2% to $146.9 million in 2025.
• The last three Total Liabilities figures came in at $146.9 million (Q4 2025), $137.5 million (Q3 2025), and $160.1 million (Q2 2025), per Business Quant data.